Search

Your search keyword '"Simonaggio, Audrey"' showing total 25 results
Start Over Author "Simonaggio, Audrey"
25 results on '"Simonaggio, Audrey"'

6. Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.

Author

Vano, Yann-Alexandre, primary, Phan, Letuan, additional, Simonaggio, Audrey, additional, Bennamoun, Mostefa, additional, Pannier, Diane, additional, Chevreau, Christine, additional, Borchiellini, Delphine, additional, Maillet, Denis, additional, Gross-Goupil, Marine, additional, Laguerre, Brigitte, additional, Tournigand, Christophe, additional, Barthelemy, Philippe, additional, Coquan, Elodie, additional, Gravis, Gwenaelle, additional, Sun, Cheng-Ming, additional, Meylan, Maxime, additional, Fridman, Wolf-Hervé, additional, Sautès-Fridman, Catherine, additional, Elaidi, Réza, additional, and Oudard, Stephane, additional

Published
2023
Full Text
View/download PDF

8. Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.

Author

Daban, Arthur, primary, Gonnin, Cecile, additional, Vano, Yann-Alexandre, additional, Phan, Letuan, additional, lillo-Lelouet, Agnes, additional, le Beller, Christine, additional, Pouchot, Jacques, additional, Fabre, Elizabeth, additional, Weiss, Laurence, additional, Tartour, Eric, additional, Oudard, Stephane, additional, Dragon Durey, Marie-Agnès, additional, and Simonaggio, Audrey, additional

Published
2022
Full Text
View/download PDF

9. Additional file 1 of Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

Author

Joseph, Adrien, Simonaggio, Audrey, Stoclin, Annabelle, Vieillard-Baron, Antoine, Geri, Guillaume, Oudard, Stéphane, Michot, Jean-Marie, Lambotte, Olivier, Azoulay, Elie, and Lemiale, Virginie

Abstract

Additional file 1: Figure S1. Eligibility and classification of patients admitted to the ICU over the study period. ICI: Immune checkpoint inhibitor.

Published
2020
Full Text
View/download PDF

10. Additional file 2 of Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

Author

Joseph, Adrien, Simonaggio, Audrey, Stoclin, Annabelle, Vieillard-Baron, Antoine, Geri, Guillaume, Oudard, Stéphane, Michot, Jean-Marie, Lambotte, Olivier, Azoulay, Elie, and Lemiale, Virginie

Abstract

Additional file 2: Figure S2. A: Pie chart of ICI treatments (n = 112). B: Pie chart of primary tumor sites (n = 112). C: Radar chart of types of irAE according to class of ICI (n = 29). Each class of ICI is represented in a different color and the number of each type of complication is featured on an axis. D: Status at ICU discharge according to the type of irAE (n = 29). The number patients alive and dead at discharge from ICU for each type of complication is featured on axis in blue and yellow color.

Published
2020
Full Text
View/download PDF

11. Additional file 3 of Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

Author

Joseph, Adrien, Simonaggio, Audrey, Stoclin, Annabelle, Vieillard-Baron, Antoine, Geri, Guillaume, Oudard, Stéphane, Michot, Jean-Marie, Lambotte, Olivier, Azoulay, Elie, and Lemiale, Virginie

Abstract

Additional file 3: Figure S3. Kaplan–Meier curves for overall survival stratified for class of immune checkpoint inhibitor (p = 0.19) and tumor type (p

Published
2020
Full Text
View/download PDF

15. CTIM-01. GLIOBLASTOMA RE-IRRADIATION: IMPACT OF CONCOMITANT CHEMOTHERAPY

Author

Epaillard, Nicolas, primary, Hammoudi, Nassim, additional, Faron, Matthieu, additional, ammari, Samy, additional, Pallud, Johan, additional, Louvel, Guillaume, additional, Lezghed, Naima, additional, Garcia, Gabriel, additional, Bockel, Sophie, additional, Copaciu, Razvan, additional, Dezami, Edouard, additional, Knafo, Steven, additional, Benadhou, Lyna, additional, Abbar, Baptiste, additional, Seknazi, Lauren, additional, Abdayem, Pamela, additional, Simonaggio, Audrey, additional, Bourcier, Kevin, additional, Dhermain, Frederic, additional, and Dumont, Sarah, additional

Published
2020
Full Text
View/download PDF

16. The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

Author

Michot, Jean-Marie, primary, Lappara, Ariane, additional, Le Pavec, Jérôme, additional, Simonaggio, Audrey, additional, Collins, Michael, additional, De Martin, Eléonora, additional, Danlos, François-Xavier, additional, Ammari, Samy, additional, Cauquil, Cécile, additional, Ederhy, Stéphane, additional, Barreau, Emmanuel, additional, Belkhir, Rakiba, additional, Berdelou, Amandine, additional, Lazarovici, Julien, additional, Chanson, Philippe, additional, Izzedine, Hassan, additional, Seferian, Andrei, additional, Le Pajolec, Christine, additional, Baldini, Capucine, additional, Martin-Romano, Patricia, additional, Mariette, Xavier, additional, Robert, Caroline, additional, Besse, Benjamin, additional, Hollebecque, Antoine, additional, Varga, Andrea, additional, Laghouati, Salim, additional, Mateus, Christine, additional, Voisin, Anne-Laure, additional, Soria, Jean-Charles, additional, Massard, Christophe, additional, Marabelle, Aurélien, additional, Champiat, Stéphane, additional, and Lambotte, Olivier, additional

Published
2020
Full Text
View/download PDF

20. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Author

Simonaggio, Audrey, primary, Michot, Jean Marie, additional, Voisin, Anne Laure, additional, Le Pavec, Jérome, additional, Collins, Michael, additional, Lallart, Audrey, additional, Cengizalp, Geoffray, additional, Vozy, Aurore, additional, Laparra, Ariane, additional, Varga, Andréa, additional, Hollebecque, Antoine, additional, Champiat, Stéphane, additional, Marabelle, Aurélien, additional, Massard, Christophe, additional, and Lambotte, Olivier, additional

Published
2019
Full Text
View/download PDF

22. The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Author

Michot, Jean-Marie, primary, Lappara, Ariane, additional, Le Pavec, Jérôme, additional, Simonaggio, Audrey, additional, Collins, Michael, additional, De Martin, Eléonora, additional, Danlos, François-Xavier, additional, Ammari, Samy, additional, Cauquil, Cécile, additional, Ederhy, Stéphane, additional, Barreau, Emmanuel, additional, Belkhir, Rakiba, additional, Berdelou, Amandine, additional, Lazarovici, Julien, additional, Chanson, Philippe, additional, Izzedine, Hassan, additional, Seferian, Andrei, additional, Le Pajolec, Christine, additional, Baldini, Capucine, additional, Romano-Martin, Patricia, additional, Mariette, Xavier, additional, Robert, Caroline, additional, Besse, Benjamin, additional, Hollebecque, Antoine, additional, Varga, Andrea, additional, Laghouati, Salim, additional, Mateus, Christine, additional, Voisin, Anne-Laure, additional, Soria, Jean-Charles, additional, Massard, Christophe, additional, Marabelle, Aurelien, additional, Champiat, Stephane, additional, and Lambotte, Olivier, additional

Published
2019
Full Text
View/download PDF

25. Resistance to cancer immunotherapy in metastatic renal cell carcinoma.

Author

Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, and Vano YA

Abstract

The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). While some mechanisms of resistance are common to several tumor types, others are specific to mccRCC. Predictive biomarkers and alternative strategies are needed to overcome this resistance. This review provides an overview of the major ICI resistance mechanisms, highlights the potential of the TME to induce resistance to ICI, and discusses the predictive biomarkers available to guide therapeutic choice., Competing Interests: Not applicable., (© The Author(s) 2020.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results